Menu Search
Equities

Genor Biopharma Holdings Ltd

67N0:STU

Genor Biopharma Holdings Ltd

Actions
  • Price (EUR)0.212
  • Today's Change-0.002 / -0.93%
  • Shares traded0.00
  • 1 Year change+34.18%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genor Biopharma Holdings Ltd, formerly JHBP CY Holdings Ltd, is China-based company mainly engaged in the research and development of biopharmaceutical products. The Company focuses on the development and commercialization of oncology and autoimmune drugs. The Company's main drugs include lerociclib (GB491), coprelotamab (GB221), geptanolimab (GB226), GB492, GB242 and GB223. The Company mainly conducts its businesses in the China market.

  • Revenue in HKD (TTM)15.75m
  • Net income in HKD-571.82m
  • Incorporated2017
  • Employees28.00
  • Location
    Genor Biopharma Holdings Ltd89 Nexus Way, Camana Bay,P.O. Box 31106SHANGHAI 201203ChinaCHN
  • Phone+86 2 161690700
  • Websitehttps://www.genorbio.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		6998:HKG since
announced		Transaction
value
Edding Group Co LtdAnnounced07 Oct 202407 Oct 2024Announced12.73%386.97m
Data delayed at least 15 minutes, as of Nov 11 2024 07:54 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.